Covid-19 Clinical Trial
Official title:
A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARD™) in Hospitalized Patients With Moderate COVID-19
Verified date | January 2021 |
Source | Sorrento Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARD™) in hospitalized patients with moderate COVID-19
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 2021 |
Est. primary completion date | January 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Evidence of moderate COVID-19, diagnosed standard RT-PCR assay or equivalent testing - Willing and able to comply with study procedures and follow-up visits - Subject or family member/caregiver must have provided written informed consent which includes signing the institutional review board approved consent form prior to participating in any study related activity. However, if obtaining written informed consent is not possible, other procedures as provided in the March 27th, 2020 FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic, Question 10, may be used. Exclusion Criteria: - Clinical signs indicative of severe COVID-19 - Rapidly progressive COVID-19 which is likely to progress to "severe" within 24 hours - Documented infection other than COVID-19 - Any medical condition that, in the Investigator's opinion, could adversely impact safety - Pregnant or lactating women - Has participated, or is participating, in a clinical research study evaluating COVID-19 convalescent plasma, monoclonal antibodies (mAbs) against SARS-CoV-2, or intravenous immunoglobulin (IVIG) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit. Note: Participants who have been prescribed hydroxychloroquine or chloroquine with or without azithromycin or other approved products for the off-label treatment of COVID-19 prior to study enrollment may be included and may continue to receive these agents so long as the dose remains stable. Additionally, any approved or authorized treatment (e.g., remdesivir, dexamethasone or treatments approved under an Emergency Use Authorization) is allowed. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sorrento Therapeutics, Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of adverse events (safety) | Types, frequencies, and severities of adverse events and their relationships to COVI-GUARD | Randomization through study completion through Day 60 | |
Primary | Incidence of treatment-emergent adverse events (safety) | Types, frequencies, and severities of treatment-emergent adverse events and their relationships to COVI-GUARD | Randomization through study completion through Day 60 | |
Primary | Incidence of serious adverse events (safety) | Types, frequencies, and severities of serious adverse events and their relationships to COVI-GUARD | Randomization through study completion through Day 60 | |
Primary | All-cause mortality at 29 and 60 days | All-cause mortality at 29 and 60 days | Randomization through Day 29 and Day 60 | |
Primary | Incidence of dose-limiting toxicities (safety) | Dose-limiting toxicities, particularly presence of acute or delayed hypersensitivity reactions | Randomization through study completion through Day 60 | |
Primary | Incidence of laboratory abnormalities (safety) | Clinically meaningful laboratory abnormalities | Randomization through study completion through Day 60 | |
Primary | SARS-CoV-2 viral load as assessed using various sample types | Plasma samples and salivary samples are taken to correlate viral load with nasopharyngeal testing at various timepoints; stool or rectal swab samples are taken if possible for additional virologic assessments | Randomization through study completion through Day 60 | |
Primary | Time to hospitalization, treatment, ICU admission, and discharge from ICU and/or hospital | Time from onset of COVID-19 symptoms to hospitalization and to treatment on Day 1, and if applicable, time to ICU admission, discharge from ICU and discharge from hospital | Randomization up to study completion through Day 60 | |
Primary | Anti-drug antibodies | Presence and levels of anti-drug antibodies (ADA) directed to COVI-GUARD | Randomization through study completion through Day 60 | |
Primary | Cytokine levels | Levels of cytokines including EGF, IFN?, IL-1ß, IL-6, IL-8, IL-10, and TNFa | Randomization through study completion through Day 60 | |
Secondary | AUC of COVI-GUARD (PK) | Area under the serum concentration-time curve (AUC) of COVI-GUARD | Randomization through study completion through Day 60 | |
Secondary | Cmax of COVI-GUARD (PK) | Maximum observed serum concentration (Cmax) of COVI-GUARD | Randomization through study completion through Day 60 | |
Secondary | t½ of COVI-GUARD (PK) | Apparent serum terminal elimination half life (t½) of COVI-GUARD | Randomization through study completion through Day 60 | |
Secondary | Tmax of COVI-GUARD (PK) | Time to Cmax (Tmax) of COVI-GUARD | Randomization through study completion through Day 60 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|